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Random forest prediction of Alzheimer’s disease using
pairwise selection from time series data.
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Abstract
Time-dependent data collected in studies of Alzheimer’s disease usually has missing and irregularly sampled data points.
For this reason time series methods which assume regular sampling cannot be applied directly to the data without a
pre-processing step. In this paper we use a machine learning method to learn the relationship between pairs of data
points at different time separations. The input vector comprises a summary of the time series history and includes both
demographic and non-time varying variables such as genetic data. The dataset used is from the 2017 TADPOLE grand
challenge which aims to predict the onset of Alzheimer’s disease using including demographic, physical and cognitive
data. The challenge is a three-fold diagnosis classification into AD, MCI and control groups, the prediction of ADAS-13
score and the normalised ventricle volume. While the competition proceeds, forecasting methods may be compared using
a leaderboard dataset selected from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and with standard metrics
for measuring accuracy. For diagnosis, we find an mAUC of 0.82, and a classification accuracy of 0.73. The results show
that the method is effective and comparable with other methods.
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1. Introduction
Alzheimer’s disease (AD) is an irreversible brain disor-
der which progressively affects cognition and behaviour,
and results in an impairment in the ability to perform
daily activities. It is the most common form of dementia
in older people, affecting about 6% of the population aged
over 65, and it increases in incidence with age. The initial
stage of AD is characterised by memory loss, and this is
the usual presenting symptom. Memory loss is one con-
stituent of mild cognitive impairment (MCI), which can be
an early sign of Alzheimer’s disease. MCI is diagnosed by
complaints of subjective memory loss (preferably corrob-
orated by a close associate or partner of the individual),
impairment of memory function, unimpaired general cog-
nition and behaviour but with no evidence of dementia
[1]. MCI does not always progress to dementia or to a
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diagnosis of Alzheimer’s disease, but those with amnestic
mild MCI, the type of MCI characterised by memory im-
pairment, are more likely to develop dementia than those
without this diagnosis. In cases where an individual does
develop Alzheimer’s disease, the phase of MCI ends with
a marked decline in cognitive function, lasting two to five
years, in which semantic memory (the recall of facts and
general knowledge) and implicit memory (the long-term,
nonconscious memory evidenced by priming effects) also
becomes degraded.
Clinical diagnosis of dementia relies on information from
a close associate or partner of the individual, and on cog-
nitive and physical examinations. Once dementia is diag-
nosed it is usually subclassified into Alzheimer’s disease,
vascular dementia or Lewy Body dementia [2][3], these
three classes making up the majority of cases. Risk fac-
tors for Alzheimer’s disease are multifarious, including so-
ciodemographic (in particular age), genetic (notably ApoE
status), and medical history (such as a diagnosis of depres-
sion). The cause of Alzheimer’s disease is not fully under-
stood, but plaques containing amyloid β–peptide (Aβ) in
brain tissue and neurofibrillary tangles containing tau pro-
tein are the primary histological features[4].
1.1. Predicting Alzheimer’s disease
The disease pathology leads to an progressive, irre-
versible loss of brain function which suggests that prospec-
tive drug therapies should be tested for efficacy as early
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in the process as possible. So there has been a demand
for predicting which individuals will develop AD as early
as possible in order to test drug therapies which might
inhibit or prevent tissue damage. There has been much
research effort put into the prediction of an AD diagno-
sis among those who are diagnosed with MCI, in par-
ticular using imaging to detect early signs of the disease
pathology: a meta analysis of 32 structural MRI or amy-
loid PET imaging studies that reported conversion to AD
in patients with MCI is given by Seo et al. [5]. This
analysis concluded that amyloid PET is a better predic-
tor of progression to AD from MCI than MRI atrophy
measures (effect size 1.32 vs 0.77), but that MRI on en-
torhinal cortex atrophy (effect size 1.26) is comparable in
prediction value to that of amyloid PET. Another com-
parison of biomarker predictivity found that the highest
predictive accuracy was achieved by combinations of amy-
loidosis and neurodegeneration biomarkers [6]. The in-
dividual biomarker with the best performance was [18F]-
fluorodeoxyglucose-positron emission tomography (FDG-
PET) which measures temporoparietal hypometabolism.
Cognitive markers have also been widely applied for
early detection of Alzheimer’s disease: a review is pre-
sented by Gainotti et al. in [7] which concluded that
measures of delayed recall are the best neuropsychological
markers of conversion from MCI to AD. Significantly, they
also suggest that MCI subjects with deficits in multiple
cognitive domains including memory may not be the best
candidates for clinical trials of disease-modifying drugs: of
this group about 50% of this will convert to AD within
2 years, making their condition less modifiable than for
those who are at an earlier stage of the disease.
1.2. The TADPOLE challenge
In evaluating a method for predicting Alzheimer’s
disease it is important to compare the results with the
current state of the art in order to calibrate the accuracy.
In the past few years there have been a number of chal-
lenges which allow comparison between methods using a
common data set and standardised evaluation metrics.
The CADDementia challenge [8] compares algorithms
for multi-class classification of AD, MCI and controls
based on structural MRI data. The Kaggle Neuroimaging
challenge https://www.kaggle.com/c/mci-prediction
[9] is based on the Kaggle machine learning platform and
uses data from the Alzheimers Disease Neuroimaging
Initiative (ADNI) http://adni.loni.usc.edu/ which is
one of the most commonly used data sets for studies of
Alzheimer’s disease[10]. The challenge involved a four-fold
classification into AD, MCI, MCI converters to AD, and
controls.
The 2017 TADPOLE grand challenge
https://tadpole.grand-challenge.org/ is currently
taking place with the evaluation to be completed by
January 2019. The challenge is a three-fold diagnosis
classification into AD, MCI and control groups, and the
prediction of ADAS-13 score and normalised brain volume
[11]. The TADPOLE challenge has the aim of predicting
the onset of Alzheimer’s disease using different modes
of measurement, including demographic, physical and
cognitive data. In common with many other studies[10],
the TADPOLE data set is also derived from ADNI. ADNI
itself is comprised of four phases: ADNI-1 (2004), ADNI-
GO (2009), ADNI-2 (2011), and ADNI-3 (2016). ADNI-1
registered 200 healthy elderly, 400 participants with MCI,
and 200 participants with AD, and the subsequent phases
continued to add participants. The TADPOLE competi-
tion involves predicting future data collected as part of
the ADNI-3 phase. The competition organisers provide
a leaderboard dataset which is separate from the main
competition and which allows prediction methods from
different teams to be evaluated. The results presented
here are derived from the TADPOLE leaderboard dataset.
Since TADPOLE data is based on ADNI, data used in
the preparation of this article were obtained from the
(ADNI) database (adni.loni.usc.edu). ADNI is led
by Principal Investigator Michael W. Weiner, MD. For
up-to-date information see www.adni-info.org.
2. Forecasting
2.1. Leaderboard data
The leaderboard dataset has a training set LB1 and a
set LB2 whose participants subsequently continued from
ADNI-1 into ADNI GO/ADNI-2 to form the leaderboard
test set LB4. LB2 is formed of ADNI-1 time points for
110 participants who who were not diagnosed with AD at
the last ADNI-1 time point. The test set LB4 comprises
the data points for those same LB2 participants during
their continuing participation in ADNI GO/ADNI-2. The
training set LB1 comprises data from participants who are
not represented in LB2. The task is to predict the diag-
nosis, ADAS-13 score and the normalised ventricle volume
for the set LB4 using set LB1 and the participant histories
recorded in LB2. The results are evaluated by comparison
with LB4 data using a variety of metrics. No informa-
tion from LB4 may be used for model training, but de-
mographic and other details about the participants who
contributed to LB4 are available from LB2, and past time
varying data such as imaging and cognitive measurements
are also available from LB2. A histogram of time series
lengths for LB1 and LB2 is shown in Figure 1.
Features for prediction are selected from the demo-
graphic, cognitive and physical data variables in the
ADNI/TADPOLE data. The physical data comprises,
among other measurements, MRI data (volumes, cortical
thickness, surface area), PET (FDG, AV45 and AV1451),
DTI (regional means of standard indices) and levels of
markers from cerebral spinal fluid (CSF).
2.2. Evaluation set
For the purposes of training we form an evaluation set
which is similar to the time series used in the leaderboard
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Figure 1: Histograms of time series lengths. Upper: training set LB1
whose time series may cover ADNI, ADNI-GO and ADNI-2. Lower:
Set LB2 which is formed only from time series in from ADNI-1.
evaluation, that is LB2 from the ADNI-1 phase and the
test set LB4 from the ADNI-GO and ADNI-2 phases. We
select the evaluation set from LB1 by choosing partici-
pants who match those of LB2 and whose ADNI-1 time
series length is similar. The post-ADNI-1 phases of this
matched evaluation set can be used to assess the prediction
accuracy, which should be similar to that of the test set
LB4. To create the evaluation set we examine each par-
ticipant time series in LB2 and find those participants in
LB1 who have a matching gender, ApoE status and age (to
within 5 years) and whose diagnosis matches at the start
and end of the ADNI-1 period. If more than one matching
participant is found we select the one who has the clos-
est match for the time series length in the ADNI-1 phase.
The demographic characteristics and ApoE status of the
participants from set LB2 and the matched evaluation set
are shown in Figure 1.
LB2 Matched set
n: 110 92
Age: 59.9 (75.1) 87.9 57.8 (75.3) 84.8
Male: 60.9% 60.9%
Female: 39.1% 39.1%
APOE 0: 70.0% 68.5%
APOE 1: 27.3% 29.4%
APOE 2: 2.7% 2.2%
Table 1: Demographic characteristics and ApoE status for partic-
ipants from the set LB2 compared with a matched evaluation set
selected from LB1. The variables shown are the sample size n, age
as minimum, mean and maximum, gender and ApoE status.
2.3. Training
We train the model using the time series from LB1 and
LB2. Points from ADNI-GO and ADNI-2 which are used
to compute prediction accuracy are not used for for train-
ing. Training is performed on 90% of the participants in
the evaluation set with accuracy measured on the remain-
ing 10%, this repeated for 10 independent splits of the
whole evaluation set. We train only on time series with
at least 4 points, this minimum having been determined
during training. The prediction variables are selected man-
ually by optimising the mean accuracy found on the eval-
uation set.
2.4. Forecasting method
The purpose of a forecasting method is to predict a pa-
tient’s condition at points in the future using demographic,
cognitive and physical data variables from time points in
the participant’s history. A common approach to auto-
matic prediction is to use time series methods which use
weighted combinations of past data points to predict the
next data point. Time series models in general encode a
mapping from an r-dimensional space to the output, where
time is not one of the input dimensions. But many time se-
ries in the training data are short and the sampling periods
are irregular, so much of the information in the training
set lies in the mapping from the time delay between mea-
surements to the output rather than in the sequence of
input values5. Another approach is to use an input space
formed of demographic variables λ, last diagnosis g(t−∆t),
time since last measurement ∆t, and map vectors in this
to the output variable gt. Again assuming additive error,
the model is,
gt = f(λ, g(t−∆t) ,∆t) + ǫt (1)
We use an ensemble of decision trees to estimate the
regression function f . Decision trees approximate the re-
gression function by partitioning the input (feature) space
into a set of rectangles [13, p305]. The training algorithm
iterates over all the features and selects the feature and
split point that gives the best partition for the training
data; this is repeated until a stopping criterion is met, such
as a minimum number of points in the rectangle. The best
partition is that that which gives the minimum total im-
purity in the two subsets that are formed. However, in our
experience decision trees own tend to overfit the training
data and perform poorly on new data, so we use a ensem-
ble of trees and poll the individual results as an estimator.
Further improvement is seen with the random forest algo-
rithm in which the features are chosen randomly at each
split point [14]. An introduction to the theory of random
forests is given in Hastie et al.[13, ch16].
5Irregular sampling and missing data can be managed by interpo-
lation or by using appropriate methods such as Gaussian process re-
gression [12], but these approaches entail making assumptions about
the distributions.
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3. Results
There are three target outcomes for prediction: 1) Diag-
nosis, 2) the ADAS-13 score, and 3) VENTS-ICV which is
the ventricles volume divided by intracranial volume. We
first present results from the evaluation set, followed by
the test set accuracy.
3.1. Evaluation set
Diagnosis. The accuracy for ten independent splits of 10%
of the evaluation set, and the training error on the full
evaluation set is shown in Table 2.
Acc(baseline) Acc mAUC BCA
Split:
61.54 69.23 0.87 0.75
73.53 73.53 0.77 0.64
69.57 69.57 0.73 0.44
52.38 52.38 0.74 0.59
86.49 86.49 0.83 0.78
73.68 86.84 0.99 0.93
70.21 74.47 0.85 0.78
62.50 78.13 0.73 0.69
91.43 91.43 0.76 0.78
88.64 88.64 0.90 0.78
Mean: 73.00 77.07 0.82 0.71
Full: 73.25 76.50 0.85 0.77
Table 2: Prediction accuracy for diagnosis in the evaluation set. The
first ten rows show the results for each partition of the evaluation
set. The final row labelled Full shows the training accuracy for
the entire set of 92 participants. The first column shows a base-
line accuracy which is obtained by using the last diagnosis as the
predictor for subsequent values. The metrics used are taken from
the TADPOLE competition and the codes reimplemented in order
to double-check the results. As a measure of accuracy we report the
multiclass area under the receiver operating curve (mAUC) and bal-
anced classification accuracy (BCA). The mAUC is based on Hand
and Till’s extension of AUC to multiple classes [15] which takes the
average AUC over all the pairs of classes, where each pair of AUCs
Aˆ(ci, cj), Aˆ(cj , ci) is itself averaged. The balanced classification ac-
curacy (BCA) is based on point scores, and is the mean of the True
Positive rate and True Negative rate.
ADAS-13 and VENTS-ICV. The prediction error for ten
independent splits of 10% of the evaluation set, and the
training error on the full evaluation set is shown in Table
3 where the first two columns show ADAS-13 results and
the next two columns show those for the ratio of ventricle
volume divided by intracranial volume.
Predictors. The predictor variables that were selected dur-
ing training are shown in Table 4. These were chosen by
starting from a base set of variables and adding variables
to increase the prediction accuracy. The set of predictors
for diagnosis and ADAS-13 are the same except that for
ADAS-13 the most recent value of the variable ADAS13 and
its slope are added.
ADAS-13 VENTS-ICV
MAE(baseline) MAE MAE(baseline) MAE
Split:
9.16 6.18 0.0034 0.0011
6.28 5.18 0.0027 0.0036
5.11 5.15 0.0033 0.0017
8.15 6.39 0.0037 0.0020
5.06 4.43 0.0028 0.0017
8.10 5.80 0.0041 0.0013
8.76 6.05 0.0048 0.0026
7.55 5.29 0.0027 0.0040
4.27 5.61 0.0042 0.0022
7.50 5.50 0.0023 0.0011
Mean: 6.99 5.56 0.0034 0.0021
Full: 6.97 5.71 0.0035 0.0021
Table 3: Mean absolute error for predicting ADAS-13 and VENTS-
ICV in the evaluation set. In each case the baseline is a prediction
using the last value of the variable to be predicted. The first ten rows
show the results for each partition of the evaluation set. The final
row labelled Full shows the result for the entire set of 92 participants.
Variable Meaning
RID Participant identifier
TIME DELAY Number of months delay
DX Diagnosis (NL or MCI or AD)
AGE Age
PTGENDER Gender
ApoE ApoE allele
FUSIFORM BL Fusiform volume at baseline
MMSE MMSE Mini-mental state examination
CDRSB CDRSB
FAQ Functional activities questionnaire
∆VENTRICLES Ventricles volume slope
∆HIPPOCAMPUS Hippocampus volume slope
∆MMSE MMSE slope
Table 4: The set of variables from which features are chosen for
predicting diagnosis and ADAS-13 values. The most recent value of
each variable is used for prediction. The MMSE value is thresholded
at 26. For predicting ADAS-13, the variables ADAS13 and ∆ADAS13
are added. For predicting VENTS-ICV, the two target variables VENTS
and ICV are predicted separately using the last value and slope of
the respective variable, with TIME DELAY also used. The prefix ∆
indicates that the slope of the variable over the history is used for
prediction.
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3.2. Test set LB4
The accuracy on the test set LB4 is shown as the
highlighted row of Table 6 which reproduces the results
from the TADPOLE competition leaderboard table. The
leaderboard shows entries in rank order where the rank
is determined by the lowest sum of individual ranks
for mAUC, ADAS-13 MAE and VENTS-ICV MAE. For
diagnosis the accuracy is mAUC=0.82 and BCA=0.73,
which compares a mean accuracy on our evaluation set
of mAUC=0.82 and BCA=0.71. The similarity of test
and evaluation errors shows that the evaluation set is well
matched to the test set and that the model has not been
overtrained. For ADAS-13 prediction the test set error
is MAE=5.19, and the evaluation set error is MAE=5.56
and for VENTS-ICV the test error is MAE=0.0023 and
the evaluation error is MAE=0.0021. The confusion ma-
trix for the test set is shown in Table 5.
Predicted diagnosis
NL MCI AD
Actual diagnosis:
NL 193 2 0
MCI 54 88 8
AD 6 45 21
Table 5: Confusion matrix for predicting the diagnosis of the test
set. In this case, the a point forecast is derived from the probabilistic
forecast by selecting the diagnosis with the highest score.
4. Discussion
In selecting participants for clinical trials, a positive
PET scan is commonly used as part of the inclusion crite-
ria. However PET imaging is expensive, so when a positive
scan is one of the trial inclusion criteria it is desirable to
avoid screening failures. So one application of predicting
Alzheimer’s disease is to preselect candidates before apply-
ing the criteria. Time series collected both in clinic and
from studies such as ADNI inevitably have missing data
points, and are of variable length. The same will be true
for clinical data collected from patients, since it is not
uncommon for appointments to be missed, and for peo-
ple to withdraw from data collection for various reasons.
Most time series prediction methods assume data which
is complete and regularly sampled, so that it has to be
pre-processed using imputation or interpolation methods
to fulfil this assumption. In this paper, rather than using
a traditional time series method we have used a machine
learning method to learn the relationship between pairs
of time points at different separations. The input vector
comprises a summary of the time series history up to that
point and the demographic and non-time varying factors
such as genetic data. This method makes no assumptions
about the dynamics of the time series, and it is applicable
to data which has missing and irregularly sampled points.
The results are better than a baseline last-value estimator,
and they validate the method as effective.
Diagnosis ADAS-13 VENTS-ICV
mAUC BCA MAE WES CPA MAE WES CPA
0.91 0.83 3.62 3.62 0.11 0.0020 0.0018 0.13
0.93 0.85 3.72 3.10 0.02 0.0020 0.0016 0.15
0.93 0.85 3.72 3.10 0.02 0.0020 0.0016 0.15
0.91 0.83 3.67 3.67 0.12 0.0024 0.0022 0.08
0.91 0.74 3.73 3.70 0.01 0.0028 0.0023 0.32
0.89 0.78 4.16 4.16 0.39 0.0023 0.0023 0.47
0.89 0.82 3.76 3.76 0.12 0.0034 0.0029 0.15
0.89 0.82 3.80 3.80 0.11 0.0034 0.0029 0.14
0.87 0.78 4.12 4.08 0.03 0.0027 0.0027 0.01
0.87 0.69 4.41 4.41 0.30 0.0026 0.0026 0.46
0.84 0.74 4.54 4.17 0.49 0.0025 0.0021 0.49
0.89 0.81 3.81 3.81 0.11 0.0057 0.0041 0.01
0.88 0.80 3.87 3.87 0.11 0.0049 0.0038 0.05
0.91 0.74 3.73 3.70 0.01 0.0092 0.0092 0.01
0.80 0.74 4.51 4.49 0.40 0.0027 0.0027 0.25
0.82 0.73 5.19 4.57 0.07 0.0023 0.0019 0.11
0.76 0.67 4.34 4.30 0.08 0.0022 0.0021 0.08
0.88 0.80 5.00 4.78 0.03 0.0030 0.0030 0.05
0.88 0.80 3.92 3.92 0.10 0.0060 0.0043 0.01
0.86 0.70 4.56 3.69 0.14 0.0034 0.0032 0.43
0.81 0.73 5.13 5.14 0.01 0.0027 0.0028 0.20
0.81 0.73 4.09 4.09 0.09 0.0045 0.0038 0.01
0.80 0.74 4.51 4.49 0.40 0.0038 0.0038 0.42
0.80 0.68 4.14 4.14 0.29 0.0040 0.0040 0.38
0.80 0.66 4.81 4.81 0.21 0.0038 0.0038 0.10
0.80 0.74 4.60 4.60 0.35 0.0041 0.0041 0.12
0.88 0.69 4.98 4.98 0.34 0.0066 0.0066 0.27
0.78 0.71 4.60 4.60 0.35 0.0041 0.0041 0.12
0.79 0.69 6.68 5.54 0.05 0.0028 0.0023 0.32
0.81 0.72 4.70 4.70 0.09 0.0070 0.0070 0.03
0.77 0.65 4.83 4.83 0.20 0.0038 0.0038 0.07
0.87 0.70 4.91 4.79 0.36 0.0073 0.0073 0.46
0.77 0.68 5.85 5.85 0.38 0.0032 0.0032 0.34
0.71 0.63 6.37 6.71 0.39 0.0026 0.0026 0.32
0.71 0.63 6.37 6.74 0.25 0.0026 0.0026 0.27
0.79 0.66 4.69 4.69 0.09 0.0093 0.0093 0.01
0.76 0.69 5.00 4.98 0.35 0.0042 0.0042 0.38
0.72 0.62 5.70 5.70 0.41 0.0036 0.0036 0.43
0.73 0.59 9.63 9.63 0.45 0.0029 0.0029 0.48
0.80 0.68 6.00 6.00 0.11 0.0075 0.0075 0.17
0.71 0.58 9.70 9.70 0.40 0.0029 0.0029 0.26
0.74 0.68 5.70 4.60 0.21 0.0070 0.0042 0.35
0.74 0.68 5.70 4.60 0.21 0.0070 0.0042 0.35
0.77 0.65 6.73 6.73 0.13 0.0094 0.0094 0.02
0.78 0.68 7.39 7.39 0.12 0.0095 0.0095 0.04
0.78 0.66 8.43 5.09 0.48 0.0096 0.0095 0.50
Table 6: Competition leaderboard table at 4 May 2018 where each
row represents an entry from a competition team and our entry is
highlighted. There are three target outcomes for prediction: 1) Diag-
nosis, 2) the ADAS-13 score, and 3) VENTS-ICV which is the ventri-
cles volume divided by intracranial volume. Predictions for diagnosis
are presented as relative probabilities for each of the three poten-
tial diagnostic categories. For the ADAS score, and the normalised
ventricles volume, we provide confidence intervals which indicate in
the limit where 50% of the predictions would lie if an experiment
were repeated many times on new data. The rank is determined by
the lowest sum of ranks from mAUC, ADAS-13 MAE and VENTS-
ICV MAE. The metrics are based on those used in the TADPOLE
competition. For diagnosis classification we use the multiclass area
under the receiver operating curve (mAUC) and balanced classifica-
tion accuracy (BCA) as described in Table 2. The metrics used for
ADAS-13 and VENTS-ICV are the mean absolute error (MAE), the
weighted error score (WES), which is the absolute error weighted by
the inverse of the confidence interval range, and the coverage prob-
ability accuracy (CPA), defined as, CPA = |j − 0.5|, where j is
the proportion of measurements falling within the 50% confidence
interval.
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